title: Basiliximab versus ATG/ALG induction in pediatric renal transplants: comparison of herpes virus profile and rejection rates.
authors.affiliation: Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada.
authors.forename: P D
authors.initials: PD
authors.lastname: Acott
authors.forename: J
authors.initials: J
authors.lastname: Lawen
authors.forename: S
authors.initials: S
authors.lastname: Lee
authors.forename: J F
authors.initials: JF
authors.lastname: Crocker
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use*; D000077552:Basiliximab; D002648:Child; D003586:Cytomegalovirus Infections / Q000453:epidemiology; D020031:Epstein-Barr Virus Infections / Q000453:epidemiology; D006084:Graft Rejection / Q000453:epidemiology*; D006566:Herpesviridae Infections / Q000453:epidemiology*; D015654:Herpesvirus 6, Human; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology / Q000502:physiology; D007683:Kidney Tubular Necrosis, Acute / Q000517:prevention & control; D011183:Postoperative Complications / Q000145:classification / Q000453:epidemiology*; D011993:Recombinant Fusion Proteins
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab